- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| OSR HOLDINGS Aktie jetzt für 0€ handeln | |||||
| Do | OSR Holdings, Inc.: Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities | 316 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / March 19, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a healthcare-focused holding company advancing innovative medical technologies, today announced that its subsidiary... ► Artikel lesen | |
| 10.03. | OSR Holdings, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 05.03. | OSR Holdings secures 180-day extension from Nasdaq | 3 | Seeking Alpha | ||
| 05.03. | Nasdaq grants OSR Holdings extension to regain compliance | 2 | Investing.com | ||
| 05.03. | OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum | 525 | ACCESS Newswire | BELLEVUE, WASHINGTON / ACCESS Newswire / March 5, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing innovative biomedical technologies, today announced that it has... ► Artikel lesen | |
| 02.02. | OSR Holdings, Inc.: CEO Statement to Shareholders | 322 | ACCESS Newswire | BELLEVUE, WASHINGTON / ACCESS Newswire / February 2, 2026 / Reaffirming Strategic Execution and Long-Term Value CreationAs the compliance deadline under the minimum bid requirement of NASDAQ approaches... ► Artikel lesen | |
| 27.01. | OSR Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.01. | OSR Holdings, Inc.: OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries | 563 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / January 27, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced the official closing of its acquisition of Woori IO, the reaffirmation of long-term equity alignment... ► Artikel lesen | |
| 14.01. | OSR Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.12.25 | Woori IO shareholders approve final step in OSR Holdings acquisition | 5 | Investing.com | ||
| 19.12.25 | Woori IO-Aktionäre stimmen Übernahme durch OSR Holdings zu | 2 | Investing.com Deutsch | ||
| 19.12.25 | OSR Holdings Inc.: Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings | 399 | PR Newswire | Company advancing dual clinical pathways, including a Samsung-supported PoC trial in Korea and a planned U.S. FDA trial with a leading California research university
... ► Artikel lesen | |
| 04.12.25 | Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target Following Major Licensing Agreement | 443 | Newsfile | New York, New York--(Newsfile Corp. - December 4, 2025) - Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (NASDAQ: OSRH), reaffirming its Buy-Emerging rating and 12-month... ► Artikel lesen | |
| 25.11.25 | OSR Holdings, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 25.11.25 | OSR Enterprises Acquires MAISENSE To Expand Next-Generation AI Compute Capabilities | 2 | pulse2.com | ||
| 25.11.25 | EQS-News: OSR Enterprises AG: Die Schweizer OSR Enterprises AG unter der Leitung von Orit Shifman gab heute die Übernahme von MAISENSE LTD bekannt, einem Hyperscale-Plasmonik-SoC-Unternehmen | 489 | EQS Group (DE) | EQS-News: OSR Enterprises AG
/ Schlagwort(e): Fusionen & Übernahmen
Die Schweizer OSR Enterprises AG unter der Leitung von Orit Shifman gab heute die Übernahme von MAISENSE LTD... ► Artikel lesen | |
| 21.11.25 | Potenzieller Lizenzdeal für Krebstherapie katapultiert OSR Holdings-Aktie nach oben | 5 | Investing.com Deutsch | ||
| 14.11.25 | OSR Holdings names Vaximm co-founder as CEO of subsidiary | 5 | Investing.com | ||
| 14.11.25 | OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion | 192 | PR Newswire | BELLEVUE, Wash., Nov. 14, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) today announced the appointment of Dr. Andreas Niethammer, M.D., Ph.D., Vaximm... ► Artikel lesen | |
| 12.11.25 | OSR Holdings, Inc. - 10-Q, Quarterly Report | - | SEC Filings |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,209 | +0,45 % | Canaccord reiterates Pacific Biosciences stock rating on new chemistry | ||
| CYTOMX THERAPEUTICS | 4,018 | -2,52 % | CytomX-Aktie: sharedealsPlus-Highflyer schießt auf +1.835% Kursgewinn | Die Aktie von CytomX Therapeutics gehört weiterhin zu den spektakulärsten Turnaround-Stories im Biotech-Sektor. Seit ihrem Vorjahrestief hat sich der Kurs des sharedealsPlus-Tipps inzwischen um rund... ► Artikel lesen | |
| CARISMA THERAPEUTICS INC | 0,127 | -100,00 % | Carisma Therapeutics Inc.: Carisma Announces Delisting from Nasdaq and SEC Deregistration | PHILADELPHIA, Dec. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (OTCID: CARM) (the "Company") today announced that its Board of Directors (the "Board") has... ► Artikel lesen | |
| CAPRICOR | 27,550 | +2,42 % | CAPRICOR THERAPEUTICS, INC. - 10-K, Annual Report | ||
| CORMEDIX | 5,300 | -2,75 % | CorMedix, Inc.: CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | - Q4 2025 Net Revenue of $128.6 million - Pro Forma Full Year 2025 Net Revenue of $401.3 million - Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million - Conference Call Scheduled... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 6,850 | -1,44 % | Minerva Neurosciences, Inc: Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum | BURLINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central... ► Artikel lesen | |
| REPLIMUNE | 5,950 | 0,00 % | Replimune, Inc.: Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update | WOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced... ► Artikel lesen | |
| VALERIO THERAPEUTICS | 0,100 | -4,76 % | Valerio Therapeutics Announces the Appointment of Professor Eric Vivier as Observer to Its Board of Directors | Regulatory News:
Valerio Therapeutics ("Valerio Therapeutics" or the "Company") (Euronext Growth Paris: ALVIO) announces the appointment of Professor Eric Vivier as an Observer to its Board of... ► Artikel lesen | |
| RANI THERAPEUTICS | 1,115 | -2,62 % | Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results | ||
| IO BIOTECH | 0,194 | 0,00 % | IO Biotech Provides Corporate Update | Raymond James engaged as financial advisorReduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing... ► Artikel lesen | |
| ALTO NEUROSCIENCE | 21,750 | -1,27 % | Stifel reiterates Buy on Alto Neuroscience stock, $33 target | ||
| CERO THERAPEUTICS | 0,095 | +0,11 % | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Provides Shareholder Update | Ongoing activities, including new engagement to relist on Nasdaq, new board member, continued advancement of Phase 1 trial into MDS patients, strategic engagement, and continued support from lead... ► Artikel lesen | |
| QIAGEN | 34,525 | -2,07 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Qiagen bei unverändertem Kursziel von 54 US-Dollar von "Hold" auf "Buy" hochgestuft. Analyst Jan Koch kehrt nach seiner Abstufung im Januar... ► Artikel lesen | |
| TANGO THERAPEUTICS | 19,400 | +0,47 % | Tango Therapeutics' (TNGX) Sees Cautious Analyst Optimism Following Earnings | ||
| DAY ONE BIOPHARMACEUTICALS | 21,380 | -0,07 % | Weekly Buzz: Bristol Myers Squibb Wins FDA Nod; EU Okays Johnson & Johnson's AKEEGA; Ipsen Withdraws Tazverik, Day One Biopharmaceuticals Acquired | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas... ► Artikel lesen |
OSR HOLDINGS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,440 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OSR HOLDINGS INC finden Sie auf Wallstreet Online.